Vital Therapies, Inc. (NASDAQ:VTL) is now up 39.14% compared to a 12-month low of $0.15. We have seen the price to move -5.02% lower and get settled at $0.21 on 3/19/2019. At recent session, it appeared stuck in a range of $0.213 to $0.229. This company shares are -100% up from its target price of $0 and the current market capitalization stands at $9.85M. The recent change has given its price a -5.51% deficit over SMA 50 and -97.85% deficit over its 52-week high. The stock witnessed -5.74% declines, -18.15% declines and -39.97% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found VTL’s volatility during a week at 10.12% and during a month it has been found around 12.78%.Vital Therapies, Inc. (VTL) Top Holders
Institutional investors currently hold around $1 million or 15.7% in VTL stock. Look at its top three institutional owners: Blackrock Inc. owns $413 thousand in Vital Therapies, Inc., which represents roughly 4.19% of the company’s market cap and approximately 41.3% of the institutional ownership. Similar statistics are true for the second largest owner, Vanguard Group Inc, which owns 692,922 shares of the stock are valued at $153 thousand. The third largest holder is Geode Capital Management, Llc, which currently holds $151 thousand worth of this stock and that ownership represents nearly 1.53% of its market capitalization.
At the end of December reporting period, 20 institutional holders increased their position in Vital Therapies, Inc. (NASDAQ:VTL) by some 1,777,127 shares, 31 decreased positions by 3,827,511 and 11 held positions by 999,614. That puts total institutional holdings at 6,604,252 shares, according to SEC filings. The stock grabbed 6 new institutional investments totaling 302,121 shares while 12 institutional investors sold out their entire positions totaling 1,438,897 shares.
Vital Therapies, Inc. (VTL) on March 5, 2019 announced results for the year ended December 31, 2018. Cash and cash equivalents at December 31, 2018, totaled $13.3 million compared to $56.9 million at December 31, 2017. The Company expects its ongoing use of funds will change based on, among other things, the strategic options that it determines to pursue.
The Company reported a net loss of $41.5 million for the year ended December 31, 2018, which compared with a net loss of $52.1 million for the prior year. This resulted in a net loss of $0.98 per share for the year ended December 31, 2018, as compared to a net loss of $1.31 per share for 2017, on both a basic and diluted basis.
Research and development expenses decreased to $24.8 million for the year ended December 31, 2018 as compared to $39.3 million for the year ended December 31, 2017. General and administrative expenses were $13.6 million for the year ended December 31, 2018, as compared to $13.3 million for the year ended December 31, 2017.